Research workspace

Finance

Public market data, research, and analysis in one place.

Finance home
Back to HK Equities

HK Equities · Finance research note

HKEX 4332 - Amgen Inc.

Research and analysis only
View analysis Browse HK Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 1128.38 B.

1.2 Competition

The industry is moderately competitive with established players and meaningful barriers to entry. Beta of N/A suggests moderate market sensitivity. Competitive advantages stem from brand, scale, or regulatory moats.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.3 Management

RoleMetric
Consensus RatingN/A

2.4 Return

MetricValue
Expected Return (Ann.)N/A
Risk / Std Dev (Ann.)N/A

Price Snapshot:

MetricValue
Last PriceN/A
Day ChangeN/A (N/A%)

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in HK$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont componentCalculationFY2025FY2024
RevenueReported revenueHK$36.75BHK$33.42B
Net incomeReported net incomeHK$7.71BHK$4.09B
Total assetsYear-end reported balanceHK$90.59BHK$91.84B
Shareholders’ equityYear-end reported balanceHK$8.66BHK$5.88B
Net marginNet income ÷ revenue20.98%12.24%
Asset turnoverRevenue ÷ total assets0.4057x0.3639x
Equity multiplierTotal assets ÷ shareholders’ equity10.4627x15.6269x
ROENet margin × asset turnover × equity multiplier89.06%69.59%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating inputValue
RevenueHK$36.75B
Prior annual revenueHK$33.42B
EBITHK$11.73B
Tax rate14.09%
NOPAT = EBIT × (1 − tax rate)HK$10.08B
Forecast start-growth basis9.95%
Forecast policylatest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building blockValue
NOPATHK$10.08B
Add: depreciation & amortisationHK$5.17B
Less: capital expenditure-HK$1.86B
Less/(add): working-capital cash-flow movement-HK$1.98B
Current unlevered FCFFHK$11.41B

Explicit FCFF forecast

Forecast yearRevenue growthNOPATD&ACapexChange in NWCFCFFPresent value
19.95%HK$11.08BHK$5.68B-HK$2.04B-HK$2.17BHK$12.54BHK$11.96B
28.09%HK$11.98BHK$6.14B-HK$3.19B-HK$2.35BHK$12.58BHK$10.91B
36.23%HK$12.72BHK$6.52B-HK$4.43B-HK$2.50BHK$12.31BHK$9.72B
44.36%HK$13.28BHK$6.81B-HK$5.72B-HK$2.61BHK$11.76BHK$8.44B
52.50%HK$13.61BHK$6.98B-HK$6.98B-HK$2.67BHK$10.94BHK$7.14B

Step 3 — Determine the Discount Rate (WACC)

WACC inputValue
Risk-free rate4.71%
Equity risk premium assumption5.50%
Beta1.00
Cost of equity10.21%
Pre-tax cost of debt4.80%
WACC9.94%
WACC validationwithin standard range

Step 4 — Estimate Terminal Value

Terminal-value inputValue
Perpetuity growth rate2.50%
Terminal valueHK$150.77B
Implied terminal EV / EBITDA6.61x
Terminal value as % of enterprise value66.09%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value componentValue
Present value of explicit FCFFHK$48.18B
Present value of terminal valueHK$93.89B
Indicated enterprise valueHK$142.07B
Discounting conventionmid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridgeValue
Indicated enterprise valueHK$142.07B
Less: gross interest-bearing debtHK$54.60B
Add: cash and equivalentsHK$9.13B
Add: affiliate investmentsHK$0.00
Less: minority interestsHK$0.00
Indicated common equity valueHK$96.59B

Step 7 — Calculate Indicative Value Per Share

Per-share outputValue
Shares used535,177,984.00
Share-count basisreported shares outstanding; option/RSU dilution data not separately available
Current market priceHK$1,850.00
DCF indicative value per shareHK$180.48
Indicative value vs. market price-90.24%

Model Integrity Checks

CheckResult
Perpetuity growth is below the risk-free ratepass
Perpetuity growth is below WACCpass
WACC is within the configured operating-company rangepass
Terminal-year FCFF is positivepass
Terminal capex converges to D&Apass
Terminal-value concentrationwithin review band
Implied price differs from spot by more than 30%review required

2.6 Investor-Style Research Screen

Educational screenResult
Buffett-inspired cash-quality checks3/4 evidenced checks
Lynch-inspired balance-and-growth checks4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:09:07.929782 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Factor-model exception: No verified adjusted-close issuer series is available for factor regression. No Fama–French loading or alpha estimate is published on an incomplete basis.

Factor models are descriptive in-sample exposure diagnostics, not forecasts, investment recommendations, or estimates of future returns. This is research and analysis only, not personalized financial advice.

hkexstockequity4332